default author photo

Robert W. Sauerwein

TropIQ Health Sciences

SCHOLARLY PAPERS

3

DOWNLOADS

150

TOTAL CITATIONS

2

Scholarly Papers (3)

1.

Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody TB31F: An Open-Label, First-in-Human, Trial in Healthy Malaria-Naïve Adults

Number of pages: 20 Posted: 10 Mar 2022
Radboud University Nijmegen - Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Radboud University Medical Center, Radboud University Nijmegen - Radboud Institute for Health Sciences, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Radboud University Medical Center, affiliation not provided to SSRN, PATH, PATH's Malaria Vaccine Initiative, affiliation not provided to SSRN, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Imperial College London, TropIQ Health Sciences, Radboud University Nijmegen - Department of Pharmacy and Radboud Center for Infectious Diseases, affiliation not provided to SSRN, affiliation not provided to SSRN, Radboud University Nijmegen - Department of Medical Microbiology and Radboud University Nijmegen - Department of Medical Microbiology
Downloads 74 (844,901)
Citation 2

Abstract:

Loading...

Malaria, Plasmodium falciparum, monoclonal antibody, transmission-reducing, transmission-blocking, TB31F

2.

Identification of Highly Potent Transmission-Blocking Human Monoclonal Antibodies to Plasmodium falciparum Pfs230 in Naturally Exposed Individuals

Number of pages: 51 Posted: 08 Sep 2022
University of Toronto - Program in Molecular Medicine, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, University of Toronto - Program in Molecular Medicine, University of Toronto - Program in Molecular Medicine, TropIQ Health Sciences, TropIQ Health Sciences, Radboud University Nijmegen - Radboud Institute for Health Sciences, AbCellera Biologics Inc., AbCellera Biologics Inc., AbCellera Biologics Inc., AbCellera Biologics Inc., PATH's Malaria Vaccine Initiative, Infectious Diseases Research Collaboration (Uganda), University of California, San Francisco (UCSF) - Department of Medicine, Stanford University - Department of Microbiology and Immunology, University of California, San Francisco (UCSF) - Department of Medicine, TropIQ Health Sciences, PATH's Malaria Vaccine Initiative, PATH's Malaria Vaccine Initiative, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology and Hospital for Sick Children Research Institute - Program in Molecular Medicine
Downloads 39 (1,196,171)

Abstract:

Loading...

Human monoclonal antibodies, malaria, natural infection, Plasmodium falciparum, transmission-blocking, Pfs230

3.

Highly Potent Naturally Acquired Human Monoclonal Antibodies Against Pfs48/45 Block Plasmodium falciparum Transmission to Mosquitoes

Number of pages: 57 Posted: 07 Sep 2022
Radboud University Nijmegen - Department of Medical Microbiology, University of Toronto - Program in Molecular Medicine, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, Radboud University Nijmegen - Department of Medical Microbiology, University of Toronto - Program in Molecular Medicine, University of Toronto - Program in Molecular Medicine, University of Toronto - Program in Molecular Medicine, TropIQ Health Sciences, TropIQ Health Sciences, TropIQ Health Sciences, AbCellera Biologics Inc., AbCellera Biologics Inc., AbCellera Biologics Inc., AbCellera Biologics Inc., Infectious Diseases Research Collaboration (Uganda), University of California, San Francisco (UCSF) - Department of Medicine, Stanford University - Department of Microbiology and Immunology, University of California, San Francisco (UCSF) - Department of Medicine, TropIQ Health Sciences, TropIQ Health Sciences, PATH's Malaria Vaccine Initiative, PATH's Malaria Vaccine Initiative, Radboud University Nijmegen - Department of Medical Microbiology, Hospital for Sick Children Research Institute - Program in Molecular Medicine and Radboud University Nijmegen - Department of Medical Microbiology
Downloads 37 (1,222,651)

Abstract:

Loading...

Malaria, Plasmodium falciparum, Human monoclonal antibodies, Crystallography, Pfs48/45, Transmission reducing activity, Transmission blocking vaccine